Obigen Pharma (7876.TWO) Stock Price

Obigen Pharma Price

CLOSED
78.20
​
Market closed

Obigen Pharma stock price

Access this data via the Eulerpool API

Obigen Pharma business model & stock analysis

Obigen Pharma Inc is a TW-based company operating in Biotechnology industry. The company is headquartered in Zhubei, Hsinchu and currently employs 57 full-time employees. The company went IPO on 2025-11-24. Obigen Pharma Inc is a Taiwan-based company mainly engaged in the research, design, development, manufacture and sale of novel botulinum toxin products. Its main product is typing A botulinum toxin, OBI-858, which is currently undergoing phase II clinical trials in Taiwan for the medical aesthetic indication of frown lines. The company operates a complete supply chain for botulinum toxin OBI-858 in the Taiwanese market, encompassing research, development, and manufacturing, and collaborates with contract research organizations (CROs) to advance the development and clinical trials of the new drugs.

Frequently asked questions about Obigen Pharma

Converted at the current exchange rate, the Obigen Pharma share trades at 2.19 EUR (78.20 TWD).

The revenue cannot currently be calculated for Obigen Pharma.

The profit cannot currently be calculated for Obigen Pharma.

The P/E ratio cannot be calculated for Obigen Pharma at the moment.

The P/S cannot be calculated for Obigen Pharma currently.

The Eulerpool Quality Score for Obigen Pharma is 2/10.

The ISIN of Obigen Pharma is TW0007876005. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Obigen Pharma is 7876.TWO. The ticker symbol is used to trade Obigen Pharma shares on the stock exchange.

Fair ValueTerminal
75.07 TWD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Taiwan
Currency
TWD
Initial public offering
Nov 24, 2025
ISIN
TW0007876005
Cusip
Y6430X107
Market capitalization
8.37 B TWDMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
5.00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-15.49 %
Last updated Oct 10, 2026, 5:57 PM

Obigen Pharma Peer Group